JP7105696B2 - 感染症を治療するステープル化細胞内ターゲティング抗微生物ペプチド - Google Patents

感染症を治療するステープル化細胞内ターゲティング抗微生物ペプチド Download PDF

Info

Publication number
JP7105696B2
JP7105696B2 JP2018545479A JP2018545479A JP7105696B2 JP 7105696 B2 JP7105696 B2 JP 7105696B2 JP 2018545479 A JP2018545479 A JP 2018545479A JP 2018545479 A JP2018545479 A JP 2018545479A JP 7105696 B2 JP7105696 B2 JP 7105696B2
Authority
JP
Japan
Prior art keywords
compound
independently
amino acid
macrocycle
bfstap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018545479A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019513696A5 (enExample
JP2019513696A (ja
Inventor
ロレン・ディ・ウォレンスキー
リダ・モータダ
Original Assignee
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド filed Critical デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Publication of JP2019513696A publication Critical patent/JP2019513696A/ja
Publication of JP2019513696A5 publication Critical patent/JP2019513696A5/ja
Priority to JP2022041655A priority Critical patent/JP7432640B2/ja
Application granted granted Critical
Publication of JP7105696B2 publication Critical patent/JP7105696B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1706—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2018545479A 2016-02-29 2017-02-28 感染症を治療するステープル化細胞内ターゲティング抗微生物ペプチド Active JP7105696B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022041655A JP7432640B2 (ja) 2016-02-29 2022-03-16 感染症を治療するステープル化細胞内ターゲティング抗微生物ペプチド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662301426P 2016-02-29 2016-02-29
US62/301,426 2016-02-29
PCT/US2017/019953 WO2017151617A1 (en) 2016-02-29 2017-02-28 Stapled intracellular-targeting antimicrobial peptides to treat infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022041655A Division JP7432640B2 (ja) 2016-02-29 2022-03-16 感染症を治療するステープル化細胞内ターゲティング抗微生物ペプチド

Publications (3)

Publication Number Publication Date
JP2019513696A JP2019513696A (ja) 2019-05-30
JP2019513696A5 JP2019513696A5 (enExample) 2020-04-09
JP7105696B2 true JP7105696B2 (ja) 2022-07-25

Family

ID=59679412

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018545479A Active JP7105696B2 (ja) 2016-02-29 2017-02-28 感染症を治療するステープル化細胞内ターゲティング抗微生物ペプチド
JP2022041655A Active JP7432640B2 (ja) 2016-02-29 2022-03-16 感染症を治療するステープル化細胞内ターゲティング抗微生物ペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022041655A Active JP7432640B2 (ja) 2016-02-29 2022-03-16 感染症を治療するステープル化細胞内ターゲティング抗微生物ペプチド

Country Status (7)

Country Link
US (3) US20170247423A1 (enExample)
EP (1) EP3423075B1 (enExample)
JP (2) JP7105696B2 (enExample)
CN (1) CN109069578A (enExample)
AU (1) AU2017228333C1 (enExample)
CA (1) CA3014442A1 (enExample)
WO (1) WO2017151617A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6918712B2 (ja) * 2015-07-02 2021-08-11 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 安定化抗微生物性ペプチド
JP7105696B2 (ja) 2016-02-29 2022-07-25 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 感染症を治療するステープル化細胞内ターゲティング抗微生物ペプチド
JP7305614B2 (ja) 2017-07-19 2023-07-10 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 抗生物質耐性細菌感染症の処置のための安定化抗菌ペプチド
WO2019090015A1 (en) * 2017-11-03 2019-05-09 Yale University Peptidic materials that traffic efficiently to the cell cytosol and nucleus
CA3078682A1 (en) 2017-12-15 2019-06-20 Dana-Farber Cancer Institute, Inc. Stabilized peptide-mediated targeted protein degradation
EP3749678A1 (en) 2018-02-07 2020-12-16 Dana Farber Cancer Institute, Inc. Cell-permeable stapled peptide modules for cellular delivery
US20200408746A1 (en) 2018-03-14 2020-12-31 Dana-Farber Cancer Institute, Inc. Stabilized Peptides for Biomarker Detection
CN109870583B (zh) * 2019-04-15 2020-03-06 德阳市人民医院 急性胰腺炎相关的代谢物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002501079A (ja) 1998-01-22 2002-01-15 サムヤン ジェネックス コーポレイション 生物学的活性を有する新規なペプチド

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861478A (en) 1987-07-06 1999-01-19 Helix Biomedix, Inc. Lytic peptides
EP0761684A3 (en) 1989-07-07 1997-07-02 Scripps Research Inst Replacement analogs for magainin peptides containing alanine residue
US5912231A (en) 1989-07-07 1999-06-15 Scripps Clinic And Research Foundation Substitution analogues of magainin peptides
US5607914A (en) 1993-01-13 1997-03-04 Pioneer Hi-Bred International, Inc. Synthetic antimicrobial peptides
US5561107A (en) 1993-06-04 1996-10-01 Demeter Biotechnologies, Ltd. Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
EP0915967A1 (en) 1996-05-28 1999-05-19 The Board Of Regents Of The University Of Michigan Engineering oral tissues
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
KR100263583B1 (ko) * 1997-05-28 2000-08-01 박종헌 항균 펩타이드의 대량 제조방법 및 그에 유용한 플라즈미드 벡타
ES2211033T3 (es) 1998-01-07 2004-07-01 Debio Recherche Pharmaceutique S.A. Acrilatos de polietilenglicol heterobifuncionales degradables y geles y conjugados derivados de dichos acrilatos.
GEP20032868B (en) 1998-01-21 2003-01-27 Merck Sharp & Dohme Triazolo-Pyridazine Derivatives as Ligands for Gaba Receptors, Methods for Their Production, Pharmaceutical Compositions Containing the Same for Treatment and/or Prevention of disorders of Central Nervous System
AU5006499A (en) 1998-07-23 2000-02-14 Intrabiotics Pharmaceuticals, Inc. Compositions and methods for the treatment or prevention of pulmonary infections
US6288212B1 (en) * 1998-08-28 2001-09-11 The University Of British Columbia Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor
US6562785B1 (en) * 1999-03-23 2003-05-13 Howard M. Shapiro Method for overcoming bacterial antibiotic resistance
DE19914817A1 (de) 1999-03-31 2000-10-05 Petry Genmedics Gmbh Dr Wirkstoffe zur Bekämpfung von bakteriellen Infektionserkrankungen
US6262071B1 (en) 1999-06-29 2001-07-17 Smithkline Beecham Corporation Methods of use of antimicrobial compounds against pathogenic amycoplasma bacteria
JP2003531101A (ja) 1999-06-29 2003-10-21 スミスクライン・ビーチャム・コーポレイション 細菌に対するフルオロキノロン化合物の使用法
US20030143234A1 (en) * 1999-08-20 2003-07-31 Wenyuan Shi Anti-microbial targeting chimeric pharmaceutical
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
BR0001870B1 (pt) 2000-05-29 2014-02-25 Peptídeo, processo de obtenção de peptídeo, formulação compreendendo peptídeo, método de prevenção de crescimento de parasitas, fungos e bactérias, método para inativar a endotoxina de bactérias gram-negativas
JP4310107B2 (ja) 2001-03-28 2009-08-05 ヘリックス バイオメディックス，インコーポレイテッド 生物活性を有する短ペプチド及び該ペプチドの使用方法
CN1158304C (zh) 2001-05-10 2004-07-21 上海华谊生物技术有限公司 蛙皮抗菌肽衍生物
MXPA03011453A (es) 2001-06-15 2004-04-05 Hoffmann La Roche Acetilacion de fragmentos de gp41.
US6620954B1 (en) 2002-03-25 2003-09-16 Eastman Chemical Company Phosphinometallocenylamides as novel ligands for asymmetric catalysis
AU2003231980A1 (en) 2002-03-29 2003-10-13 Buck Institute Identification of apoptotic peptides and methods of use thereof
PT2332968T (pt) 2003-11-05 2016-08-17 Harvard College Péptidos alfa-helicoidais adequados para a activação ou inibição da morte celular
US7745390B2 (en) * 2005-05-23 2010-06-29 The Board Of Trustees Of The Leland Stanford Junior University Antimicrobial peptides
ES2487967T3 (es) 2006-04-20 2014-08-25 Pfizer Products Inc. Compuestos amido heterocíclicos condensados con fenilo para la prevención y el tratamiento de enfermedades mediadas por la glucoquinasa
WO2008058575A1 (de) 2006-11-17 2008-05-22 Osram Gesellschaft mit beschränkter Haftung Modulares flächen- leuchtsystem
WO2008086042A2 (en) 2007-01-10 2008-07-17 Chisari Francis V Preventing infection by a measles or respiratory syncytial virus
EP2118123B1 (en) 2007-01-31 2015-10-14 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP3159352B1 (en) 2007-03-28 2023-08-02 President and Fellows of Harvard College Stitched polypeptides
EP2146698A2 (en) 2007-05-24 2010-01-27 New York Blood Center, Inc. Rapidly dispersible vaginal tablet that provides a bioadhesive gel
CA2700925C (en) 2007-09-26 2016-08-23 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
EP2247606B1 (en) 2008-01-23 2019-08-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of viral infections
US20100069308A1 (en) 2008-06-06 2010-03-18 Chorny Iiya Surfaces containing antibacterial polymers
US8586707B2 (en) 2008-09-16 2013-11-19 The Research Foundation Of State University Of New York Stapled peptides and method of synthesis
US20100099614A1 (en) 2008-10-06 2010-04-22 Hodges Robert S Antimicrobial Peptides and Methods of Use
EP2352507A4 (en) 2008-11-24 2012-04-25 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES
GB0821687D0 (en) 2008-11-28 2008-12-31 Secr Defence Peptides
KR20100065639A (ko) 2008-12-08 2010-06-17 건국대학교 산학협력단 새로운 피시딘 유도체 항생 펩타이드 및 그 용도
EP3124494B1 (en) 2008-12-09 2019-06-19 Dana-Farber Cancer Institute, Inc. Methods and compositions for specific modulation of mcl-1
WO2012006598A2 (en) 2010-07-09 2012-01-12 Dana-Farber Cancer Institute, Inc. Stabilized insulinotropic peptides and methods of use
US9822165B2 (en) 2009-06-18 2017-11-21 Dana-Farber Cancer Institute, Inc. Hydrocarbon stapled stabilized alpha-helices of the HIV-1 GP41 membrane proximal external region
ES2579806T3 (es) * 2009-06-26 2016-08-16 Katholieke Universiteit Leuven, K.U. Leuven R&D Agentes antimicrobianos
US20130139930A1 (en) 2009-12-18 2013-06-06 Latitude 18, Inc. Inorganic phosphate corrosion resistant coatings
AU2012242502B2 (en) 2011-04-15 2016-07-28 Dana-Farber Cancer Institute, Inc. Targeting deregulated WNT signaling in cancer using stabilized alpha-helices of BCL-9
DE102012203547A1 (de) * 2012-03-07 2013-09-12 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Antimikrobielle Peptide
WO2013039857A1 (en) 2011-09-12 2013-03-21 modeRNA Therapeutics Engineered nucleic acids and methods of use thereof
WO2013049567A1 (en) 2011-09-29 2013-04-04 The Broad Institute, Inc. Compounds for the treatment of mycobacterial infections
US8669226B2 (en) * 2011-10-07 2014-03-11 Morehouse School Of Medicine Antimicrobial compositions and methods of use thereof
US10077290B2 (en) 2011-12-29 2018-09-18 Dana-Farber Cancer Institute, Inc. Stabilized antiviral fusion helices
WO2013148677A1 (en) * 2012-03-26 2013-10-03 University Of Florida Research Foundation, Inc. Antimicrobial compounds and their use in treating plant disease
RU2694758C2 (ru) 2012-12-20 2019-07-16 Раджив Бхушан Антимикробные композиции
CN103164738B (zh) 2013-02-06 2015-09-30 厦门盛华电子科技有限公司 一种基于移动支付多通道数字认证的手机用户识别卡
EP2991665A4 (en) 2013-03-13 2016-11-09 Harvard College STACKED AND GRAFTED POLYPEPTIDES AND USES THEREOF
US10308926B2 (en) 2013-03-15 2019-06-04 Dana-Farber Cancer Institute, Inc. Stablized EZH2 peptides
US10087215B2 (en) 2013-03-15 2018-10-02 Dana-Farber Cancer Institute, Inc. Stabilized SOS1 peptides
WO2015070912A1 (en) 2013-11-14 2015-05-21 Lysando Ag Modified el188 endolysin sequence
WO2015112980A2 (en) 2014-01-24 2015-07-30 The Regents Of The University Of Colorado, A Body Corporate Dermaseptin-type and piscidin-type antimicrobial peptides
WO2015138494A1 (en) * 2014-03-10 2015-09-17 Georges Belfort Anti-microbial peptides and method for designing novel anti-microbial peptides
US10507227B2 (en) 2014-04-15 2019-12-17 The Hospital For Sick Children Cationic antimicrobial peptides
JP6918712B2 (ja) 2015-07-02 2021-08-11 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 安定化抗微生物性ペプチド
WO2017147283A1 (en) 2016-02-23 2017-08-31 Dana-Farber Cancer Institute, Inc. Method for generating cell-penetrating stapled peptides that lack nonspecific membrane-lytic properties for therapeutic targeting
JP7105696B2 (ja) 2016-02-29 2022-07-25 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 感染症を治療するステープル化細胞内ターゲティング抗微生物ペプチド
JP7305614B2 (ja) * 2017-07-19 2023-07-10 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 抗生物質耐性細菌感染症の処置のための安定化抗菌ペプチド
US20230116760A1 (en) 2019-12-16 2023-04-13 Dana-Farber Cancer Institute, Inc. Structurally-stabilized oncolytic peptides and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002501079A (ja) 1998-01-22 2002-01-15 サムヤン ジェネックス コーポレイション 生物学的活性を有する新規なペプチド

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Design of stable antimicrobial peptides through hydrocarbon stapling - Digital Repository"，2011, retrieved on 2021.1.22., retrieved from t he Internet, <URL:http://invenio.nusl.cz/record/80987>
Amino Acids, 2012, DOI: 10.1007/s00726-012-1283-1
BBRC, 1996, Vol.218, pp.408-413
Bioorganic & Medicinal Chemistry Letters, 2013, Vol.23, pp.6717-6720
Bioorganic & Medicinal Chemistry Letters, 2015, Vol.25, pp.4016-4019
Biophysical Journal, 2013, Vol.104, pp.1923-1932

Also Published As

Publication number Publication date
AU2017228333B2 (en) 2021-09-23
JP2022095666A (ja) 2022-06-28
CA3014442A1 (en) 2017-09-08
EP3423075B1 (en) 2024-04-03
EP3423075A1 (en) 2019-01-09
US20170247423A1 (en) 2017-08-31
AU2017228333C1 (en) 2022-03-10
CN109069578A (zh) 2018-12-21
US12391733B2 (en) 2025-08-19
WO2017151617A1 (en) 2017-09-08
AU2017228333A1 (en) 2018-08-23
EP3423075A4 (en) 2019-11-20
JP2019513696A (ja) 2019-05-30
JP7432640B2 (ja) 2024-02-16
US11945846B2 (en) 2024-04-02
US20200308236A1 (en) 2020-10-01
US20240343765A1 (en) 2024-10-17

Similar Documents

Publication Publication Date Title
JP7360419B2 (ja) 安定化抗微生物性ペプチド
JP7432640B2 (ja) 感染症を治療するステープル化細胞内ターゲティング抗微生物ペプチド
US20170360881A1 (en) Peptidomimetic macrocycles and uses thereof
US11325955B2 (en) Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections
US20150231199A1 (en) Peptides and their uses
JP2008514586A (ja) 新規な抗菌剤
HK1252893B (en) Stabilized anti-microbial peptides
WO2019167034A1 (en) Compounds and methods for eliciting antimicrobial activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210623

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220316

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220316

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220329

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220428

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220510

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220607

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220621

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220712

R150 Certificate of patent or registration of utility model

Ref document number: 7105696

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250